CompoAtlas

SIROP DU PERE MICHEL FAMILLE

Food supplement declared in France, declaration No 2021-11-1025, decision dated 22 November 2021

SIROP DU PERE MICHEL FAMILLE (BIOLIGO) is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Eucalyptus radiata 0.0015 ml per day, Pinus sylvestris 0.0015 ml per day, Cinnamomum camphora 0.0015 ml per day, Salvia officinalis 0.001 ml per day, Copper. None of the rules we check flags an issue with its declared composition; vitamin and mineral doses are not published by Compl'Alim and are therefore not checked.

Brand
BIOLIGO
Food business operator placing the product on the market
PROPOS'NATURE
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Syrup
Daily dose
5 ml
Not recommended (according to the manufacturer)
Breastfeeding women, Pregnant women
Objectives stated by the manufacturer (these are not authorised claims)
Immunity

Declaration 229484, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Eucalyptus radiata A.Cunn. ex DC.Essence (feuille)Distillation0.0015 ml
Pinus sylvestris L.Essence (feuille)Distillation0.0015 ml
Cinnamomum camphora (L.) J. PreslEssence (feuille)Distillation0.0015 ml
Salvia officinalis L.FeuilleExtrait fluide aqueux0.001 ml

Other active ingredients

NamePer day
Propolisnot declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
cupric sulphateCopper5,000 µg2,000 µg

Other ingredients

fructose, Eau déminéralisée, Sirop de maltose

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Label warnings

DEMANDER L’AVIS À UN PROFESSIONNEL DE SANTÉ AVANT UTILISATION.

Regulatory points

None of the rules we check applies to the declared ingredients.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Salvia officinalis L.
    Read the warning, when it applies and the studies cited

    SAGE - SALVIA OFFICINALIS - Buccal

    Cautions and warnings

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last (for) more than 7 days.

    Health Canada monograph dated 28 March 2025

    SAGE -SALVIA OFFICINALIS Oral

    Cautions and warnings

    Condition of application: Carminative, Diaphoretic, Antihidrotic, Antigalactagogue.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Contraindications

    Condition of application: All products.

    Do not use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Bradley 2006; Mills and Bone 2005).

    Sources cited by Health Canada (3)
    • Bradley PR, editor. 2006: Bradley PR, editor. British Herbal Compendium Volume 2: A Handbook of Scientific Information on Widely Used Plant Drug-Companion to the British Herbal Pharmacopoeia. Bournemouth (GB): British Herbal Medicine Association; 2006.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Raton (FL): Taylor and Francis Group; 2013.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Do not use if you have a seizure disorder such as epilepsy (Gardner and McGuffin 2013; Bradley 2006; Mills and Bone 2005).

    Sources cited by Health Canada (3)
    • Bradley PR, editor. 2006: Bradley PR, editor. British Herbal Compendium Volume 2: A Handbook of Scientific Information on Widely Used Plant Drug-Companion to the British Herbal Pharmacopoeia. Bournemouth (GB): British Herbal Medicine Association; 2006.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Raton (FL): Taylor and Francis Group; 2013.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Health Canada monograph dated 10 January 2025

  • Propolis
    Read the warning, when it applies and the studies cited

    PROPOLIS - Oral

    Cautions and warnings

    Condition of application: All uses.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are allergic to bee products, poplar tree products, or balsam of Peru (Brinker 2010; Marcucci 1995; Valsecchi and Cainelli 1984; Melli et al. 1983; Rudzki and Gryzwa 1983).

    Sources cited by Health Canada (5)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Marcucci MC. Propolis: chemical composition, biological properties and therapeutic activity. Apidologie 1995;26:83-89.
    • Melli MC, Giorgini S, Sertoli A. Occupational dermatitis in a bee-keeper. Contact Dermatitis 1983;9(5):427-428. PubMed Case report
    • Rudzki E, Grzywa Z. Dermatitis from propolis. Contact Dermatitis 1983;9(1):40-45. PubMed
    • Valsecchi R, Cainelli T. Dermatitis from propolis. Contact Dermatitis 1984;11(5):317. PubMed

    Condition of application: Relief of sore throat/mouth and throat infections.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (PPRC 2020; Scully 2006; Hsu et al. 2004; Teraki and Shiohara 2001; Machácková 1988; Hausen et al. 1987; Valsecchi and Cainelli 1984; Melli et al. 1983; Rudzki and Grzywa 1983).

    Sources cited by Health Canada (9)
    • Hausen BM, Wollenweber E, Senff H, Post B. Propolis allergy (II): the sensitizing properties of 1,1-dimethylallyl caffeic acid ester. Contact Dermatitis 1987;17:171-177. PubMed Case report
    • Hsu CY, Chiang WC, Weng TI, Chen WJ, Yuan A. Laryngeal edema and anaphalactic shock after topical propolis use for acute pharyngitis. American Journal of Emergency Medicine 2004;22(5):432-433. PubMed Case report
    • Machackova J. The incidence of allergy to propolis in 605 consecutive patients patch tested in Prague. Contact Dermatitis 1988;18:210-212. PubMed
    • Melli MC, Giorgini S, Sertoli A. Occupational dermatitis in a bee-keeper. Contact Dermatitis 1983;9(5):427-428. PubMed Case report
    • PPRC 2020: Pharmacopoeia of the People's Republic of China, Volume 1, English edition. Beijing (CN): The State Pharmacopoeia Commission of the People's Republic of China; 2020.
    • Rudzki E, Grzywa Z. Dermatitis from propolis. Contact Dermatitis 1983;9(1):40-45. PubMed
    • Scully C. Propolis: A background (Letter). British Dental Journal 2006;200(7):359-360. PubMed
    • Teraki Y, Shiohara T. Propolis-induced granulomatous contact dermatitis accompanied by marked lymphadenopathy. British Journal of Dermatology 2001;144:1277-1278. PubMed Case report
    • Valsecchi R, Cainelli T. Dermatitis from propolis. Contact Dermatitis 1984;11(5):317. PubMed

    Health Canada monograph dated 30 May 2025

    PROPOLIS Buccal

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are allergic to bee products, poplar tree products, or balsam of Peru (Brinker 2010; Marcucci 1995; Valsecchi and Cainelli 1984; Melli et al. 1983; Rudzki and Gryzwa 1983).

    Sources cited by Health Canada (5)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Marcucci MC. Propolis: chemical composition, biological properties and therapeutic activity. Apidologie 1995;26:83-89.
    • Melli MC, Giorgini S, Sertoli A. Occupational dermatitis in a bee-keeper. Contact Dermatitis 1983;9(5):427-428. PubMed Case report
    • Rudzki E, Grzywa Z. Dermatitis from propolis. Contact Dermatitis 1983;9(1):40-45. PubMed
    • Valsecchi R, Cainelli T. Dermatitis from propolis. Contact Dermatitis 1984;11(5):317. PubMed

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: All products, except those not swallowed (e.g., gargles, rinses).

    Ask a health care practitioner/health care provider/health care professional/doctor/ physician before use if you are pregnant or breastfeeding.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (PPRC 2020; Scully 2006; Hsu et al. 2004; Teraki and Shiohara 2001; Machácková 1988; Hausen et al. 1987; Valsecchi and Cainelli 1984; Melli et al. 1983; Rudzki and Grzywa 1983).

    Sources cited by Health Canada (8)
    • Hausen BM, Wollenweber E, Senff H, Post B. Propolis allergy (II): the sensitizing properties of 1,1-dimethylallyl caffeic acid ester. Contact Dermatitis 1987;17:171-177. PubMed Case report
    • Hsu CY, Chiang WC, Weng TI, Chen WJ, Yuan A. Laryngeal edema and anaphalactic shock after topical propolis use for acute pharyngitis. American Journal of Emergency Medicine 2004;22(5):432-433. PubMed Case report
    • Melli MC, Giorgini S, Sertoli A. Occupational dermatitis in a bee-keeper. Contact Dermatitis 1983;9(5):427-428. PubMed Case report
    • PPRC 2020: Pharmacopoeia of the People’s Republic of China, Volume 1, English edition. Beijing (CN): The State Pharmacopoeia Commission of the People’s Republic of China; 2020.
    • Rudzki E, Grzywa Z. Dermatitis from propolis. Contact Dermatitis 1983;9(1):40-45. PubMed
    • Scully C. Propolis: A background (Letter). British Dental Journal 2006;200(7):359-360. PubMed
    • Teraki Y, Shiohara T. Propolis-induced granulomatous contact dermatitis accompanied by marked lymphadenopathy. British Journal of Dermatology 2001;144:1277-1278. PubMed Case report
    • Valsecchi R, Cainelli T. Dermatitis from propolis. Contact Dermatitis 1984;11(5):317. PubMed

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 29 May 2026

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : BIOLIGO

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “SIROP DU PERE MICHEL FAMILLE (BIOLIGO): composition and regulation”, https://compoatlas.com/en/supplements/products/229484-sirop-du-pere-michel-famille, updated 15 November 2026.

List recorded in 2021. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line